Dr. Finanger is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 Sw Sam Jackson Park Rd
Cdrc-P
Portland, OR 97239Phone+1 503-494-5856Fax+1 503-494-2370
Education & Training
- Johns Hopkins UniversityFellowship, Neuromuscular Medicine (Neurology), 2008 - 2009
- Johns Hopkins UniversityFellowship, Child Neurology, 2005 - 2008
- Mayo Clinic College of MedicineClass of 2003
Certifications & Licensure
- OR State Medical License 2009 - 2025
- WA State Medical License 2023 - 2025
- MD State Medical License 2008 - 2010
- MN State Medical License 2004 - 2005
- American Board of Psychiatry and Neurology Neurology with Special Qualification in Child Neurology
- American Board of Psychiatry and Neurology Neuromuscular Medicine
Clinical Trials
- A Study of Tadalafil for Duchenne Muscular Dystrophy Start of enrollment: 2013 Sep 01
- A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy Start of enrollment: 2014 Aug 19
- Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Start of enrollment: 2015 Jun 30
Publications & Presentations
PubMed
- 1307 citationsNusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyRichard S. Finkel, Eugenio Mercuri, Basil T. Darras, Anne M. Connolly, Nancy L. Kuntz
The New England Journal of Medicine. 2017-11-01 - 48 citationsLongitudinal timed function tests in Duchenne muscular dystrophy: ImagingDMD cohort natural history.Harneet Arora, Rebecca J. Willcocks, Donovan J. Lott, Ann T. Harrington, Claudia R. Senesac
Muscle & Nerve. 2018-11-01 - 126 citationsMulticenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.Rebecca J. Willcocks, William D. Rooney, William T. Triplett, Sean C. Forbes, Donovan J. Lott
Annals of Neurology. 2016-02-19
Press Mentions
- Local Girl Receives First at-Home Treatment for Rare DiseaseNovember 13th, 2020
- Catabasis Pharmaceuticals Reports First Quarter 2020 Financial Results and Reviews Business ProgressMay 12th, 2020
- Edasalonexent May Limit Disease Progression in Boys with Duchenne MD, Phase 1/2 Trial ShowsMarch 1st, 2019
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: